IONIS PHARMACEUTICALS INC Contracts & Agreements
150 Contracts & Agreements
- Business Finance (27 contracts)
- Business Operations (39)
- Human Resources (14)
- Intellectual Property (22)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (45)
- Collaboration and License Agreement by and between the Registrant and Novartis Pharma AG dated as of August 2, 2023. Portions of this exhibit have been omitted because they are... (Filed With SEC on November 2, 2023)
- Amended and Restated Lease Agreement between the Registrant and Lots 21 & 22 Owner (DE) LLC dated as of August 21, 2023. Portions of this exhibit have been omitted because they... (Filed With SEC on November 2, 2023)
- Research, Development, and License Agreement by and among the Registrant, F. Hoffmann-La Roche Ltd., and Hoffmann-La Roche Inc. dated as of September 26, 2023. Portions of this... (Filed With SEC on November 2, 2023)
- Amendment No. 3 dated April 27, 2023 to the Collaboration and License Agreement by and between the Registrant and BicycleTx Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on August 9, 2023)
- First Amendment dated June 15, 2023 to the Purchase and Sale Agreement by and between the Registrant and Oxford I Asset Management USA Inc. dated as of October 20, 2022 (Filed With SEC on August 9, 2023)
- Letter Agreement dated June 29, 2023 in reference to the Collaboration and License Agreement dated December 6, 2021 by and between Akcea Therapeutics, Inc. and AstraZeneca AB.... (Filed With SEC on August 9, 2023)
- Indenture, dated as of June 12, 2023, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee (Filed With SEC on June 12, 2023)
- Second Amended Non-Employee Director Compensation Policy (Filed With SEC on May 3, 2023)
- Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors Stock Option Plan, as amended on March 14, 2023 (Filed With SEC on May 3, 2023)
- Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Restricted Stock Units granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002... (Filed With SEC on May 3, 2023)
- HTT Research, Development, Option and License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated as of April. 8, 2013 (Filed With SEC on May 3, 2023)
- Form of Option Agreement for Options granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors Stock Option Plan (Filed With SEC on February 22, 2023)
- Form of Option Agreement under the 2011 Equity Incentive Plan (Filed With SEC on February 22, 2023)
- Form of Time-Vested Restricted Stock Unit Agreement for Restricted Stock Units granted under the 2011 Equity Incentive Plan (Filed With SEC on February 22, 2023)
- Forms of Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement for Performance Based Restricted Stock Units granted beginning... (Filed With SEC on February 22, 2023)
- Amendment No. 2 dated July 28, 2022 to the Collaboration and License Agreement by and between the Registrant and BicycleTx Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on November 9, 2022)
- First Amendment dated July 8, 2022 to Factor B Development, Collaboration, Option and License Agreement by and between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La... (Filed With SEC on August 9, 2022)
- Amended and Restated Ionis Pharmaceuticals, Inc. Severance Benefit Plan (Filed With SEC on May 4, 2022)
- Description of the Registrants Securities (Filed With SEC on February 25, 2022)
- Forms of Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement for Performance Based Restricted Stock Units granted under the... (Filed With SEC on February 25, 2022)
- Fourth Amended and Restated Strategic Advisory Services Agreement by and between the Registrant and B. Lynne Parshall, dated February 22, 2022 (Filed With SEC on February 25, 2022)
- Amendment No. 1 dated December 17, 2021 to the Collaboration and License Agreement by and between the Registrant and BicycleTX Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on February 25, 2022)
- Amended and Restated Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc., And Biogen MA Inc. Dated July 12,... (Filed With SEC on November 3, 2021)
- COLLABORATION AND LICENSE AGREEMENT between BICYCLETX LIMITED and IONIS PHARMACEUTICALS, INC. Dated as of July 9, 2021 (Filed With SEC on November 3, 2021)
- Non-Employee Director Compensation Policy Amended June 2, 2021 (Filed With SEC on August 4, 2021)
- [Signature page to follow] (Filed With SEC on May 5, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on May 5, 2021)
- Indenture, dated as of April 12, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 13, 2021)
- Form of Convertible Note Hedge Confirmation (Filed With SEC on April 13, 2021)
- Form of Warrant Confirmation (Filed With SEC on April 13, 2021)
- Forms of Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement for Performance Based Restricted Stock Units granted under the... (Filed With SEC on February 24, 2021)
- Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 22, 2014. Portions of this exhibit have been omitted because... (Filed With SEC on February 24, 2021)
- First Amendment to Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 21, 2016. Portions of this exhibit have been... (Filed With SEC on February 24, 2021)
- Third Amended and Restated Strategic Advisory Services Agreement by and between the Registrant and B. Lynne Parshall, dated February 22, 2021 (Filed With SEC on February 24, 2021)
- Amendment No. 3 dated December 17, 2020 to the Strategic Collaboration Agreement by and between the Registrant and AstraZeneca AB dated July 31, 2015. Portions of this exhibit... (Filed With SEC on February 24, 2021)
- Strategic Advisory Services Agreement by and between the Registrant and Stanley T. Crooke, dated December 17, 2020 (Filed With SEC on February 24, 2021)
- Side Letter dated December 31, 2020 to the New Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and... (Filed With SEC on February 24, 2021)
- Agreement and Plan of Merger, dated as of August 30, 2020, among Akcea Therapeutics, Inc., Ionis Pharmaceuticals, Inc. and Avalanche Merger Sub, Inc (Filed With SEC on August 31, 2020)
- Side Letter dated June 11, 2020 to the Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between... (Filed With SEC on August 5, 2020)
- Amendment No. 2 to the Strategic Collaboration Agreement by and between the Registrant and AstraZeneca AB dated July 31, 2015 (portions of the exhibit have been omitted because... (Filed With SEC on August 5, 2020)
- Description of the Registrants Securities (Filed With SEC on March 2, 2020)
- Letter Agreement between the Registrant, Akcea Therapeutics, Inc., and Pfizer Inc., dated October 4, 2019. Portions of this exhibit have been omitted because they are both (i) not... (Filed With SEC on March 2, 2020)
- Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement (Filed With SEC on January 17, 2020)
- Second Amended and Restated Advisory Services Agreement dated January 9, 2020 (Filed With SEC on January 10, 2020)
- Indenture, dated as of December 19, 2019, by and between Ionis Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee (Filed With SEC on December 23, 2019)
- Amendment No. 1 to the Neurology III Agreement between the Registrant and Biogen MA Inc., dated August 16, 2019 (portions of the exhibit have been omitted because they are both... (Filed With SEC on November 6, 2019)
- Amendment #8 to the Research, Development and License Agreement between the Registrant, Glaxo Group Limited and Glaxosmithkline Intellectual Property Development Limited, dated... (Filed With SEC on November 6, 2019)
- Consent to Collateral Addition and Amendment to Loan Documents between the Registrant, Ionis Gazelle, LLC, Wells Fargo Bank, National Association, as Trustee for the Benefit of... (Filed With SEC on November 6, 2019)
- Amendment No. 1 to Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and... (Filed With SEC on August 8, 2019)
- Amended and Restated Advisory Services Agreement dated March 22, 2019 (Filed With SEC on March 26, 2019)
- Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan (Filed With SEC on March 26, 2019)
- Factor B Development Collaboration, Option and License Agreement by and between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated October 9, 2018.... (Filed With SEC on March 1, 2019)
- Second Amendment to Research Collaboration, Option and License Agreement of December 22, 2014, by and between Ionis Pharmaceuticals, Inc. and Janssen Biotech Inc. Portions of this... (Filed With SEC on November 6, 2018)
- Ionis Severance Benefit Plan and Summary Plan Description dated October 18, 2018 (Filed With SEC on October 19, 2018)
- Strategic Advisory Services Agreement, dated as of January 15, 2018, by and between B. Lynne Parshall and Ionis Pharmaceuticals, Inc (Filed With SEC on May 7, 2018)
- Development, Commercialization, Collaboration, and License Agreement, dated as of March 14, 2018, by and between Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc (Filed With SEC on May 7, 2018)
- Amended and Restated Services Agreement, dated as of March 14, 2018, by and between Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc (Filed With SEC on May 7, 2018)
- IONIS CODE OF ETHICS AND BUSINESS CONDUCT PHILOSOPHY OF IONIS CODE OF ETHICS AND BUSINESS CONDUCT (Filed With SEC on February 28, 2018)
- ISIS PHARMACEUTICALS, INC. (Filed With SEC on February 28, 2018)
- IONIS PHARMACEUTICALS, INC. EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS AGREEMENT (Filed With SEC on February 28, 2018)
- Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma AG (Filed With SEC on May 9, 2017)
- STOCK PURCHASE AGREEMENT (Filed With SEC on May 9, 2017)
- AMENDMENT #1 TO THE LICENSE AGREEMENT, DATED MAY 1ST, 2015 (Filed With SEC on May 9, 2017)
- 225 Binney Street, Cambridge, MA 02142 " Phone ###-###-#### " www.biogen.com (Filed With SEC on March 1, 2017)
- AMENDMENT NO.3 (Filed With SEC on May 5, 2016)
- AMENDMENT #7 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on May 5, 2016)
- AMENDMENT NO. 2 TO LINE OF CREDIT AGREEMENT (Filed With SEC on February 26, 2016)
- Amendment No.1 to Loan Documents between Ionis Pharmaceuticals, Inc. and Morgan Stanley Private Bank, National Association dated December 30, 2015 (Filed With SEC on January 5, 2016)
- CONFIDENTIAL TREATMENT REQUESTEDUNDER 17 C.F.R 200.80(B)4, AND 240.24B-2 Exhibit 10.1ConfidentialExecution CopyLicense Agreement Between Isis Pharmaceuticals, Inc., And Bayer... (Filed With SEC on August 5, 2015)
- SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 5, 2015)
- AMENDMENT #1 TO HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT (Filed With SEC on May 5, 2015)
- [Signature page follows] (Filed With SEC on March 2, 2015)
- Research Collaboration, Option and License Agreement Between Isis Pharmaceuticals, Inc. And Janssen Biotech Inc. (Filed With SEC on March 2, 2015)
- AMENDMENT NO.2 (Filed With SEC on March 2, 2015)
- ISIS PHARMACEUTICALS, INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of November 17, 2014 1.00% Convertible Senior Notes due 2021 (Filed With SEC on November 21, 2014)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 7, 2014)
- Amended and Restated Collaboration and License Agreement (Filed With SEC on November 7, 2014)
- Amendment to Amended and Restated Collaboration and License Agreement relating to [***] (Filed With SEC on November 7, 2014)
- Amendment No. 3 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated July 10, 2013. Portions of this exhibit have been omitted... (Filed With SEC on August 4, 2014)
- Amendment #4 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated April 10, 2014. Portions of this exhibit have been omitted and... (Filed With SEC on August 4, 2014)
- Amendment #5 to the Research, Development and License Agreement among the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated June... (Filed With SEC on August 4, 2014)
- Letter Agreement Amendment between the Registrant and Biogen Idec International Holding Ltd dated January 27, 2014. Portions of this exhibit have been omitted and separately filed... (Filed With SEC on May 6, 2014)
- HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT AMONG ISIS PHARMACEUTICALS, INC., AND F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC. (Filed With SEC on August 6, 2013)
- Isis Pharmaceuticals, Inc. 9,000,000 shares of common stock, par value $0.001 per share Underwriting Agreement (Filed With SEC on May 9, 2013)
- INDEMNITY AGREEMENT (Filed With SEC on February 28, 2013)
- AMENDMENT #2 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on February 28, 2013)
- COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND ASTRAZENECA AB (Filed With SEC on February 28, 2013)
- NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC MA INC. (Filed With SEC on February 28, 2013)
- Isis Pharmaceuticals, Inc. Requests that the marked portions of the exhibit be granted confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. (Filed With SEC on November 6, 2012)
- ISIS PHARMACEUTICALS, INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August 13, 2012 2.75% Convertible Senior Notes due 2019 (Filed With SEC on August 13, 2012)
- DMPK RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC MA INC. (Filed With SEC on August 6, 2012)
- THIRD AMENDMENT TO LOAN AGREEMENT (Filed With SEC on August 6, 2012)
- ISIS PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (AMENDED & RESTATED 2002 NON-EMPLOYEE DIRECTORS STOCK OPTION PLAN) (Filed With SEC on August 6, 2012)
- DEVELOPMENT, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC INTERNATIONAL HOLDING LTD (Filed With SEC on May 9, 2012)
- RESEARCH AGREEMENT (Filed With SEC on November 8, 2011)
- AMENDMENT #1 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on August 8, 2011)
- SECOND AMENDMENT TO LEASE AGREEMENT (Filed With SEC on August 8, 2011)
- SECOND AMENDMENT TO LOAN AGREEMENT (Filed With SEC on March 1, 2011)
- FIRSTAMENDMENT TOCOLLABORATION RESEARCH AND LICENSE AGREEMENT (Filed With SEC on November 5, 2010)
- COLLABORATION AND LICENSE AGREEMENT between REGULUS THERAPEUTICS INC. And SANOFI-AVENTIS (Filed With SEC on August 9, 2010)
- NON-EXCLUSIVE TECHNOLOGY ALLIANCE AND OPTION AGREEMENT between REGULUS THERAPEUTICS INC. and SANOFI-AVENTIS (Filed With SEC on August 9, 2010)
- AMENDMENT NUMBER ONE TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on August 9, 2010)
- AMENDMENT NUMBER ONE TO THE FOUNDING INVESTOR RIGHTS AGREEMENT (Filed With SEC on August 9, 2010)
- AMENDMENT #1 TO THE PRODUCTDEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on May 7, 2010)
- EXCLUSIVE LICENSEAND NONEXCLUSIVE OPTION AGREEMENT BETWEEN GLAXO GROUPLIMITED AND REGULUSTHERAPEUTICS INC. (Filed With SEC on May 7, 2010)
- LEASEAGREEMENT (Filed With SEC on May 7, 2010)
- ARTICLE36 OPTIONTO EXTEND (Filed With SEC on May 7, 2010)
- RESEARCH, DEVELOPMENT AND LICENSEAGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND GLAXO GROUP LIMITED (Filed With SEC on May 7, 2010)
- DRUGDEVELOPMENT AND LICENSE OPTION AGREEMENT BETWEEN ELILILLY AND COMPANY AND ISISPHARMACEUTICALS, INC. December 2,2009 (Filed With SEC on March 1, 2010)
- AMENDED &RESTATED LICENSE AGREEMENT (Filed With SEC on March 1, 2010)
- FIRST AMENDMENT TO LOAN AGREEMENT (Filed With SEC on March 1, 2010)
- AMENDMENTNO. 1 TO AMENDEDAND RESTATED LICENSE AGREEMENT (Filed With SEC on March 1, 2010)
- LOAN AGREEMENT (Filed With SEC on February 26, 2009)
- REGULUS THERAPEUTICS LLC EMPLOYMENT AGREEMENT (Filed With SEC on February 26, 2009)
- C O N F I D E N T I A L PRE-CLINICAL DEVELOPMENTCOLLABORATION AGREEMENT (Filed With SEC on February 26, 2009)
- STOCK PURCHASE AGREEMENT by and among IBIS BIOSCIENCES, INC., ISIS PHARMACEUTICALS, INC. and ABBOTT MOLECULAR INC. Dated: December 17, 2008 (Filed With SEC on February 26, 2009)
- EXHIBIT A SEPARATIONAGREEMENT (Filed With SEC on December 5, 2008)
- EXHIBIT A SEPARATIONAGREEMENT (Filed With SEC on December 5, 2008)
- Isis Policy andProcedures Manual (Filed With SEC on December 5, 2008)
- AMENDEDAND RESTATED LICENSE AGREEMENT (Filed With SEC on November 10, 2008)
- LICENSE AND RESEARCH AGREEMENT (Filed With SEC on May 12, 2008)
- AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 12, 2008)
- CONFIDENTIAL TREATMENTREQUESTED UNDER 17 C.F.R 200.80(b)4,AND 240.24b-2 (Filed With SEC on May 12, 2008)
- STRATEGICALLIANCE MASTER AGREEMENT AMONG IBISBIOSCIENCES, INC. ISISPHARMACEUTICALS, INC. AND ABBOTTMOLECULAR INC. January 30, 2008 (Filed With SEC on May 12, 2008)
- CALL OPTION AGREEMENT BY AND AMONG ISIS PHARMACEUTICALS, INC., IBIS BIOSCIENCES, INC. AND ABBOTT MOLECULAR INC. January 30, 2008 (Filed With SEC on May 12, 2008)
- AMENDMENT NO. 1 TO SALE AGREEMENT (Filed With SEC on October 17, 2007)
- RETENTION AGREEMENT (Filed With SEC on September 27, 2007)
- COLLABORATIONAND LICENSE AGREEMENT between ISIS PHARMACEUTICALS, INC. and BRISTOL-MYERSSQUIBB COMPANY (Filed With SEC on August 9, 2007)
- AMENDMENT NO. 1 (Filed With SEC on August 9, 2007)
- LICENSEAGREEMENT (Filed With SEC on May 10, 2007)
- EXHIBIT A FORM OF SEPARATION AGREEMENT (Filed With SEC on February 7, 2007)
- ISISPHARMACEUTICALS, INC. (Filed With SEC on January 24, 2007)
- REGISTRATION RIGHTSAGREEMENT BY AND BETWEEN ISIS PHARMACEUTICALS,INC., AS ISSUER AND LEHMAN BROTHERS INC., ASREPRESENTATIVE OF THE INITIAL PURCHASERS DATED AS OF JANUARY 23,2007 (Filed With SEC on January 24, 2007)
- $125,000,000 ISISPHARMACEUTICALS, INC. 2 58%Convertible Subordinated Notes due 2027 PURCHASEAGREEMENT (Filed With SEC on January 24, 2007)
- MANUFACTURING, COMMERCIALIZATION AND DEVELOPMENT AGREEMENT (Filed With SEC on November 7, 2006)
- CONFIDENTIALTREATMENT REQUESTED UNDER 17 C.F.R. 200.80(b)4, AND 240.24b-2 (Filed With SEC on May 10, 2006)
- CONFIDENTIAL TREATMENTREQUESTED UNDER 17 C.F.R. 200.80(b)4, AND 240.24b-2 (Filed With SEC on May 10, 2006)
- CONFIDENTIAL TREATMENTREQUESTED UNDER 17 C.F.R. 200.80(b)4, AND 240.24b-2 (Filed With SEC on May 10, 2006)
- CONFIDENTIAL TREATMENTREQUESTED UNDER 17 C.F.R. 200.80(b)4, AND 240.24b-2 (Filed With SEC on May 10, 2006)
- ISISPHARMACEUTICALS, INC. WARRANTTO PURCHASE COMMON STOCK (Filed With SEC on May 10, 2006)
- LEASEAGREEMENT (Filed With SEC on November 9, 2005)
- RESTATEDISIS PHARMACEUTICALS, INC. 10B5-1 TRADING PLAN (Filed With SEC on November 9, 2005)
- SECONDAMENDED AND RESTATED COLLABORATION AGREEMENT BETWEEN ELI LILLYAND COMPANY AND ISISPHARMACEUTICALS, INC. August 5,2005 (Filed With SEC on November 9, 2005)
- NOTICE OF GRANT AWARD (Filed With SEC on November 9, 2005)
- SUBCONTRACT AGREEMENT Time and Material /Labor Hour (Filed With SEC on November 9, 2005)
- COLLABORATIVE RESEARCH AGREEMENT (Filed With SEC on August 9, 2005)
- AGREEMENT FOR PURCHASE AND SALE OF 2280 Faraday Avenue San Diego, CA 92008 June 28, 2005 (Filed With SEC on August 9, 2005)
- OMBApp-al 2700-0042 (Filed With SEC on November 8, 2004)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on August 6, 2004)
- SUBCONTRACT AGREEMENT Time and Material / Labor Hour (Filed With SEC on May 10, 2004)